Schering-Plough: Drugmaker, Heal Thyself
Schering-Plough: Drugmaker, Heal Thyself It has a potential blockbuster and a savvy new CEO. With federal probers and Claritin’s expired patent to deal with, it will need both
Schering-Plough: Drugmaker, Heal Thyself It has a potential blockbuster and a savvy new CEO. With federal probers and Claritin’s expired patent to deal with, it will need both
Geron’s the Biotech of the Day Geron saw its shares rise $1.72, or 25%, to $8.68 after the company said it has received a patent that could be used in stem-cell research. The process would be used, if it’s ever needed, to provide an additional level of safety for cell therapies made from human embryonic […]
Get new actionable insights and updates from BiotechBlog